{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:05:45Z","timestamp":1792699545342,"version":"4.5.0"},"publisher-location":"New York, NY","reference-count":79,"publisher":"Springer New York","isbn-type":[{"value":"9781493990641","type":"print"},{"value":"9781493990658","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-1-4939-9065-8_9","type":"book-chapter","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T13:22:54Z","timestamp":1548940974000},"page":"155-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Current Use of Adenovirus Vectors and Their Production Methods"],"prefix":"10.1007","author":[{"given":"Ekramy E.","family":"Sayedahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"issue":"3","key":"9_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3181\/00379727-84-20714","volume":"84","author":"WP Rowe","year":"1953","unstructured":"Rowe WP, Huebner RJ, Gilmore LK et al (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84(3):570\u2013573","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3212","key":"9_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1126\/science.124.3212.119","volume":"124","author":"JF Enders","year":"1956","unstructured":"Enders JF, Bell JA, Dingle JH et al (1956) Adenoviruses: group name proposed for new respiratory-tract viruses. Science 124(3212):119\u2013120","journal-title":"Science"},{"issue":"Pt 11","key":"9_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","volume":"84","author":"AJ Davison","year":"2003","unstructured":"Davison AJ, Benko M, Harrach B (2003) Genetic content and evolution of adenoviruses. J Gen Virol 84(Pt 11):2895\u20132908. https:\/\/doi.org\/10.1099\/vir.0.19497-0","journal-title":"J Gen Virol"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","volume":"41","author":"KJ Ewer","year":"2016","unstructured":"Ewer KJ, Lambe T, Rollier CS et al (2016) Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol 41:47\u201354. https:\/\/doi.org\/10.1016\/j.coi.2016.05.014","journal-title":"Curr Opin Immunol"},{"key":"9_CR5","doi-asserted-by":"publisher","first-page":"06","DOI":"10.5772\/19757","volume-title":"Viral gene therapy","author":"C Su","year":"2011","unstructured":"Su C (2011) Adenovirus-based gene therapy for cancer. In: Xu K (ed) Viral gene therapy. InTech, Rijeka, p 06. https:\/\/doi.org\/10.5772\/19757"},{"issue":"1","key":"9_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/mp100219n","volume":"8","author":"S Pesonen","year":"2011","unstructured":"Pesonen S, Kangasniemi L, Hemminki A (2011) Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 8(1):12\u201328. https:\/\/doi.org\/10.1021\/mp100219n","journal-title":"Mol Pharm"},{"issue":"4","key":"9_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10(4):616\u2013629. https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.013","journal-title":"Mol Ther"},{"issue":"2","key":"9_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.virusres.2013.09.013","volume":"178","author":"SV Vemula","year":"2013","unstructured":"Vemula SV, Amen O, Katz JM et al (2013) Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res 178(2):398\u2013403. https:\/\/doi.org\/10.1016\/j.virusres.2013.09.013","journal-title":"Virus Res"},{"issue":"2","key":"9_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/157488509788185123","volume":"4","author":"A Sharma","year":"2009","unstructured":"Sharma A, Tandon M, Bangari DS et al (2009) Adenoviral vector-based strategies for cancer therapy. Curr Drug ther 4(2):117\u2013138","journal-title":"Curr Drug ther"},{"issue":"1\u20132","key":"9_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, Chirmule N, Lee FS et al (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1\u20132):148\u2013158","journal-title":"Mol Genet Metab"},{"issue":"17","key":"9_CR11","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1089\/10430349950016555","volume":"10","author":"BG Harvey","year":"1999","unstructured":"Harvey BG, Worgall S, Ely S et al (1999) Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Hum Gene Ther 10(17):2823\u20132837. https:\/\/doi.org\/10.1089\/10430349950016555","journal-title":"Hum Gene Ther"},{"issue":"4","key":"9_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jcb.22328","volume":"108","author":"AK Zaiss","year":"2009","unstructured":"Zaiss AK, Machado HB, Herschman HR (2009) The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 108(4):778\u2013790. https:\/\/doi.org\/10.1002\/jcb.22328","journal-title":"J Cell Biochem"},{"issue":"3","key":"9_CR13","doi-asserted-by":"publisher","first-page":"e33428","DOI":"10.1371\/journal.pone.0033428","volume":"7","author":"A Pandey","year":"2012","unstructured":"Pandey A, Singh N, Vemula SV et al (2012) Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One 7(3):e33428. https:\/\/doi.org\/10.1371\/journal.pone.0033428","journal-title":"PLoS One"},{"issue":"4","key":"9_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","volume":"28","author":"TC Mast","year":"2010","unstructured":"Mast TC, Kierstead L, Gupta SB et al (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28(4):950\u2013957. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.145","journal-title":"Vaccine"},{"issue":"4","key":"9_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1128\/cvi.00467-09","volume":"17","author":"WD Pratt","year":"2010","unstructured":"Pratt WD, Wang D, Nichols DK et al (2010) Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17(4):572\u2013581. https:\/\/doi.org\/10.1128\/cvi.00467-09","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"9_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WS Wold","year":"2013","unstructured":"Wold WS, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13(6):421\u2013433","journal-title":"Curr Gene Ther"},{"issue":"9","key":"9_CR17","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/v2092013","volume":"2","author":"SS Seregin","year":"2010","unstructured":"Seregin SS, Amalfitano A (2010) Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses 2(9):2013\u20132036. https:\/\/doi.org\/10.3390\/v2092013","journal-title":"Viruses"},{"issue":"9","key":"9_CR18","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1073\/pnas.94.9.4686","volume":"94","author":"MA Kay","year":"1997","unstructured":"Kay MA, Meuse L, Gown AM et al (1997) Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse\u2009liver. Proc Natl Acad Sci U S A 94(9):4686\u20134691","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"9_CR19","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","volume":"91","author":"JF Engelhardt","year":"1994","unstructured":"Engelhardt JF, Ye X, Doranz B et al (1994) Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 91(13):6196\u20136200","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","volume":"24","author":"DS Bangari","year":"2006","unstructured":"Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24(7):849\u2013862. https:\/\/doi.org\/10.1016\/j.vaccine.2005.08.101","journal-title":"Vaccine"},{"key":"9_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/B978-0-12-800276-6.00019-X","volume-title":"Adenoviral vectors for gene therapy","author":"SK Mittal","year":"2016","unstructured":"Mittal SK, Ahi YS, Vemula SV (2016) 19 - xenogenic adenoviral vectors A2 - curiel. In: David T (ed) Adenoviral vectors for gene therapy, 2nd edn. Academic Press, San Diego, pp 495\u2013528. https:\/\/doi.org\/10.1016\/B978-0-12-800276-6.00019-X","edition":"2"},{"issue":"5","key":"9_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/mt.2008.12","volume":"16","author":"N Singh","year":"2008","unstructured":"Singh N, Pandey A, Jayashankar L et al (2008) Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 16(5):965\u2013971. https:\/\/doi.org\/10.1038\/mt.2008.12","journal-title":"Mol Ther"},{"issue":"1","key":"9_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1006\/viro.2000.0350","volume":"272","author":"S Moffatt","year":"2000","unstructured":"Moffatt S, Hays J, HogenEsch H et al (2000) Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 272(1):159\u2013167. https:\/\/doi.org\/10.1006\/viro.2000.0350","journal-title":"Virology"},{"issue":"2","key":"9_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.virol.2009.06.029","volume":"392","author":"X Li","year":"2009","unstructured":"Li X, Bangari DS, Sharma A et al (2009) Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 392(2):162\u2013168. https:\/\/doi.org\/10.1016\/j.virol.2009.06.029","journal-title":"Virology"},{"issue":"4","key":"9_CR25","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.bbrc.2005.04.058","volume":"331","author":"DS Bangari","year":"2005","unstructured":"Bangari DS, Sharma A, Mittal SK (2005) Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun 331(4):1478\u20131484. https:\/\/doi.org\/10.1016\/j.bbrc.2005.04.058","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"9_CR26","doi-asserted-by":"publisher","first-page":"7689","DOI":"10.1128\/jvi.77.13.7689-7695.2003","volume":"77","author":"A Ehrhardt","year":"2003","unstructured":"Ehrhardt A, Xu H, Kay MA (2003) Episomal Persistence of Recombinant Adenoviral Vector Genomes during the Cell Cycle In Vivo. J Virol 77(13):7689\u20137695. https:\/\/doi.org\/10.1128\/jvi.77.13.7689-7695.2003","journal-title":"J Virol"},{"issue":"5","key":"9_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/156652307782151452","volume":"7","author":"MP Seiler","year":"2007","unstructured":"Seiler MP, Cerullo V, Lee B (2007) Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 7(5):297\u2013305","journal-title":"Curr Gene Ther"},{"key":"9_CR28","unstructured":"Gene Therapy Clinical Trials Worldwide (2017). Available from; http:\/\/www.abedia.com\/wiley\/vectors.php ). http:\/\/www.abedia.com\/wiley\/vectors.php"},{"issue":"205","key":"9_CR29","doi-asserted-by":"publisher","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","volume":"5","author":"F Smaill","year":"2013","unstructured":"Smaill F, Jeyanathan M, Smieja M et al (2013) A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5(205):205ra134. https:\/\/doi.org\/10.1126\/scitranslmed.3006843","journal-title":"Sci Transl Med"},{"issue":"10","key":"9_CR30","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","volume":"10","author":"SV Vemula","year":"2010","unstructured":"Vemula SV, Mittal SK (2010) Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther 10(10):1469\u20131487. https:\/\/doi.org\/10.1517\/14712598.2010.519332","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"9_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"YS Ahi","year":"2011","unstructured":"Ahi YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11(4):307\u2013320","journal-title":"Curr Gene Ther"},{"issue":"7","key":"9_CR32","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/jvi.02192-06","volume":"81","author":"J Zhu","year":"2007","unstructured":"Zhu J, Huang X, Yang Y (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81(7):3170\u20133180. https:\/\/doi.org\/10.1128\/jvi.02192-06","journal-title":"J Virol"},{"issue":"5","key":"9_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/gt.2010.1","volume":"17","author":"A Sharma","year":"2010","unstructured":"Sharma A, Tandon M, Ahi YS et al (2010) Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 17(5):634\u2013642. https:\/\/doi.org\/10.1038\/gt.2010.1","journal-title":"Gene Ther"},{"issue":"10","key":"9_CR34","doi-asserted-by":"publisher","first-page":"e0186244","DOI":"10.1371\/journal.pone.0186244","volume":"12","author":"AO Hassan","year":"2017","unstructured":"Hassan AO, Amen O, Sayedahmed EE et al (2017) Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses. PLoS One 12(10):e0186244. https:\/\/doi.org\/10.1371\/journal.pone.0186244","journal-title":"PLoS One"},{"issue":"8","key":"9_CR35","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.3390\/v9080234","volume":"9","author":"EH Kim","year":"2017","unstructured":"Kim EH, Han GY, Nguyen H (2017) An adenovirus-vectored influenza vaccine induces durable cross-protective hemagglutinin stalk antibody responses in mice. Viruses 9(8):E234. https:\/\/doi.org\/10.3390\/v9080234","journal-title":"Viruses"},{"issue":"22","key":"9_CR36","doi-asserted-by":"publisher","first-page":"13300","DOI":"10.1128\/jvi.01532-14","volume":"88","author":"A Kamlangdee","year":"2014","unstructured":"Kamlangdee A, Kingstad-Bakke B, Anderson TK et al (2014) Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol 88(22):13300\u201313309. https:\/\/doi.org\/10.1128\/jvi.01532-14","journal-title":"J Virol"},{"issue":"8","key":"9_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1086\/529522","volume":"197","author":"MA Hoelscher","year":"2008","unstructured":"Hoelscher MA, Singh N, Garg S et al (2008) A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 197(8):1185\u20131188. https:\/\/doi.org\/10.1086\/529522","journal-title":"J Infect Dis"},{"issue":"6","key":"9_CR38","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.vaccine.2015.12.062","volume":"34","author":"W Cao","year":"2016","unstructured":"Cao W, Liepkalns JS, Hassan AO et al (2016) A highly immunogenic vaccine against A\/H7N9 influenza virus. Vaccine 34(6):744\u2013749. https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.062","journal-title":"Vaccine"},{"issue":"11","key":"9_CR39","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","volume":"12","author":"RD Vries de","year":"2016","unstructured":"de Vries RD, Rimmelzwaan GF (2016) Viral vector-based influenza vaccines. Hum Vaccin Immunother 12(11):2881\u20132901. https:\/\/doi.org\/10.1080\/21645515.2016.1210729","journal-title":"Hum Vaccin Immunother"},{"issue":"9509","key":"9_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s0140-6736(06)68076-8","volume":"367","author":"MA Hoelscher","year":"2006","unstructured":"Hoelscher MA, Garg S, Bangari DS et al (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367(9509):475\u2013481. https:\/\/doi.org\/10.1016\/s0140-6736(06)68076-8","journal-title":"Lancet"},{"issue":"8","key":"9_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","volume":"23","author":"KR Kampen Van","year":"2005","unstructured":"Van Kampen KR, Shi Z, Gao P et al (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8):1029\u20131036. https:\/\/doi.org\/10.1016\/j.vaccine.2004.07.043","journal-title":"Vaccine"},{"issue":"5","key":"9_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4172\/2155-6113.1000461","volume":"6","author":"JD Fuchs","year":"2015","unstructured":"Fuchs JD, Bart PA, Frahm N et al (2015) Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals. J AIDS Clin Res 6(5):461. https:\/\/doi.org\/10.4172\/2155-6113.1000461","journal-title":"J AIDS Clin Res"},{"issue":"15","key":"9_CR43","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan ID, Gibani MM, Sewell R et al (2016) Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines: a randomized clinical trial. JAMA 315(15):1610\u20131623. https:\/\/doi.org\/10.1001\/jama.2016.4218","journal-title":"JAMA"},{"issue":"5","key":"9_CR44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/jir850","volume":"205","author":"GA O'Hara","year":"2012","unstructured":"O'Hara GA, Duncan CJ, Ewer KJ et al (2012) Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205(5):772\u2013781. https:\/\/doi.org\/10.1093\/infdis\/jir850","journal-title":"J Infect Dis"},{"issue":"5","key":"9_CR45","doi-asserted-by":"publisher","first-page":"e0005527","DOI":"10.1371\/journal.pntd.0005527","volume":"11","author":"M Osman","year":"2017","unstructured":"Osman M, Mistry A, Keding A et al (2017) A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 11(5):e0005527. https:\/\/doi.org\/10.1371\/journal.pntd.0005527","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"9_CR46","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood JE, DeZure AD, Stanley DA et al (2017) Chimpanzee adenovirus vector ebola vaccine. N Engl J Med 376(10):928\u2013938. https:\/\/doi.org\/10.1056\/NEJMoa1410863","journal-title":"N Engl J Med"},{"issue":"1","key":"9_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1473-3099(15)00362-x","volume":"16","author":"MD Tapia","year":"2016","unstructured":"Tapia MD, Sow SO, Lyke KE et al (2016) Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16(1):31\u201342. https:\/\/doi.org\/10.1016\/s1473-3099(15)00362-x","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"9_CR48","doi-asserted-by":"publisher","first-page":"e00720","DOI":"10.1128\/jvi.00720-16","volume":"91","author":"CM Crosby","year":"2017","unstructured":"Crosby CM, Matchett WE, Anguiano-Zarate SS et al (2017) Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses. J Virol 91(2):e00720. https:\/\/doi.org\/10.1128\/jvi.00720-16","journal-title":"J Virol"},{"issue":"2","key":"9_CR49","first-page":"325","volume":"59","author":"Y Li","year":"1999","unstructured":"Li Y, Pong RC, Bergelson JM et al (1999) Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59(2):325\u2013330","journal-title":"Cancer Res"},{"issue":"1","key":"9_CR50","doi-asserted-by":"publisher","first-page":"e0147173","DOI":"10.1371\/journal.pone.0147173","volume":"11","author":"YH Shen","year":"2016","unstructured":"Shen YH, Yang F, Wang H et al (2016) Arg-Gly-Asp (RGD)-modified E1A\/E1B double mutant adenovirus enhances antitumor activity in prostate cancer cells in vitro and in mice. PLoS One 11(1):e0147173. https:\/\/doi.org\/10.1371\/journal.pone.0147173","journal-title":"PLoS One"},{"issue":"1","key":"9_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nm.2270","volume":"17","author":"H Wang","year":"2011","unstructured":"Wang H, Li ZY, Liu Y et al (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17(1):96\u2013104. https:\/\/doi.org\/10.1038\/nm.2270","journal-title":"Nat Med"},{"issue":"2","key":"9_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.1821","volume":"207","author":"K Biedermann","year":"2005","unstructured":"Biedermann K, Vogelsang H, Becker I et al (2005) Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol 207(2):199\u2013206. https:\/\/doi.org\/10.1002\/path.1821","journal-title":"J Pathol"},{"issue":"6","key":"9_CR53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2340\/0001555576417420","volume":"76","author":"H Harada","year":"1996","unstructured":"Harada H, Iwatsuki K, Ohtsuka M et al (1996) Abnormal desmoglein expression by squamous cell carcinoma cells. Acta Derm Venereol 76(6):417\u2013420","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"9_CR54","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/sj.jid.5700849","volume":"127","author":"CJ Schmitt","year":"2007","unstructured":"Schmitt CJ, Franke WW, Goerdt S et al (2007) Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein. J Invest Dermatol 127(9):2191\u20132206. https:\/\/doi.org\/10.1038\/sj.jid.5700849","journal-title":"J Invest Dermatol"},{"issue":"9","key":"9_CR55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3727\/096504013x13657689383139","volume":"20","author":"SY Lee","year":"2013","unstructured":"Lee SY, Park HR, Rhee J et al (2013) Therapeutic effect of oncolytic adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma. Oncol Res 20(9):419\u2013425. https:\/\/doi.org\/10.3727\/096504013x13657689383139","journal-title":"Oncol Res"},{"issue":"1","key":"9_CR56","doi-asserted-by":"publisher","first-page":"e0147211","DOI":"10.1371\/journal.pone.0147211","volume":"11","author":"B Vera","year":"2016","unstructured":"Vera B, Martinez-Velez N, Xipell E et al (2016) Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. PLoS One 11(1):e0147211. https:\/\/doi.org\/10.1371\/journal.pone.0147211","journal-title":"PLoS One"},{"key":"9_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki T, Pesonen S, Hemminki A et al (2016) Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer 4:17. https:\/\/doi.org\/10.1186\/s40425-016-0121-5","journal-title":"J Immunother Cancer"},{"issue":"20","key":"9_CR58","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","volume":"7","author":"X Danthinne","year":"2000","unstructured":"Danthinne X, Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7(20):1707\u20131714. https:\/\/doi.org\/10.1038\/sj.gt.3301301","journal-title":"Gene Ther"},{"issue":"1","key":"9_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham FL, Smiley J, Russell WC et al (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36(1):59\u201374. https:\/\/doi.org\/10.1099\/0022-1317-36-1-59","journal-title":"J Gen Virol"},{"issue":"Suppl 1","key":"9_CR60","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1002\/jgm.503","volume":"6","author":"A Kamen","year":"2004","unstructured":"Kamen A, Henry O (2004) Development and optimization of an adenovirus production process. J Gene Med 6(Suppl 1):S184\u2013S192. https:\/\/doi.org\/10.1002\/jgm.503","journal-title":"J Gene Med"},{"issue":"13","key":"9_CR61","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","volume":"9","author":"FJ Fallaux","year":"1998","unstructured":"Fallaux FJ, Bout A, van der Velde I et al (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9(13):1909\u20131917. https:\/\/doi.org\/10.1089\/hum.1998.9.13-1909","journal-title":"Hum Gene Ther"},{"issue":"1","key":"9_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.virol.2005.09.029","volume":"345","author":"JA Howe","year":"2006","unstructured":"Howe JA, Pelka P, Antelman D et al (2006) Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors. Virology 345(1):220\u2013230. https:\/\/doi.org\/10.1016\/j.virol.2005.09.029","journal-title":"Virology"},{"issue":"6","key":"9_CR63","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1161\/01.ATV.20.6.1452","volume":"20","author":"S Wen","year":"2000","unstructured":"Wen S, Schneider DB, Driscoll RM et al (2000) Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler Thromb Vasc Biol 20(6):1452\u20131458","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"9_CR64","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1073\/pnas.92.9.3854","volume":"92","author":"K Mitani","year":"1995","unstructured":"Mitani K, Graham FL, Caskey CT et al (1995) Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 92(9):3854\u20133858","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"9_CR65","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/sj.gt.3300995","volume":"6","author":"R Parks","year":"1999","unstructured":"Parks R, Evelegh C, Graham F (1999) Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6(9):1565\u20131573. https:\/\/doi.org\/10.1038\/sj.gt.3300995","journal-title":"Gene Ther"},{"issue":"Suppl 1","key":"9_CR66","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","volume":"12","author":"R Alba","year":"2005","unstructured":"Alba R, Bosch A, Chillon M (2005) Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12(Suppl 1):S18\u2013S27. https:\/\/doi.org\/10.1038\/sj.gt.3302612","journal-title":"Gene Ther"},{"issue":"24","key":"9_CR67","doi-asserted-by":"publisher","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","volume":"93","author":"R Parks","year":"1996","unstructured":"Parks R, Chen L, Anton M et al (1996) A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging\u2009signal. Proc Natl Acad Sci U S A 93(24):13565\u201313570","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9_CR68","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/JVI.71.3.1842-1849.1997","volume":"71","author":"S Hardy","year":"1997","unstructured":"Hardy S, Kitamura M, Harris-Stansil T et al (1997) Construction of adenovirus vectors through Cre-lox recombination. J Virol 71(3):1842\u20131849","journal-title":"J Virol"},{"issue":"9","key":"9_CR69","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/v2091886","volume":"2","author":"F Vetrini","year":"2010","unstructured":"Vetrini F, Ng P (2010) Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2(9):1886\u20131917. https:\/\/doi.org\/10.3390\/v2091886","journal-title":"Viruses"},{"issue":"1","key":"9_CR70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/JVI.37.1.171-180.1981","volume":"37","author":"ND Stow","year":"1981","unstructured":"Stow ND (1981) Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis. J Virol 37(1):171\u2013180","journal-title":"J Virol"},{"issue":"5","key":"9_CR71","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","volume":"95","author":"TC He","year":"1998","unstructured":"He TC, Zhou S, da Costa LT et al (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95(5):2509\u20132514","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9_CR72","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/JVI.70.7.4805-4810.1996","volume":"70","author":"C Chartier","year":"1996","unstructured":"Chartier C, Degryse E, Gantzer M et al (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70(7):4805\u20134810","journal-title":"J Virol"},{"issue":"1","key":"9_CR73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jviromet.2011.06.016","volume":"177","author":"C Wu","year":"2011","unstructured":"Wu C, Lei X, Wang J et al (2011) Generation of a replication-deficient recombinant human adenovirus type 35 vector using bacteria-mediated homologous recombination. J Virol Methods 177(1):55\u201363. https:\/\/doi.org\/10.1016\/j.jviromet.2011.06.016","journal-title":"J Virol Methods"},{"issue":"5","key":"9_CR74","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nprot.2007.135","volume":"2","author":"J Luo","year":"2007","unstructured":"Luo J, Deng ZL, Luo X et al (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2(5):1236\u20131247. https:\/\/doi.org\/10.1038\/nprot.2007.135","journal-title":"Nat Protoc"},{"issue":"16","key":"9_CR75","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1089\/10430349950016708","volume":"10","author":"P Ng","year":"1999","unstructured":"Ng P, Parks RJ, Cummings DT et al (1999) A high-efficiency Cre\/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 10(16):2667\u20132672. https:\/\/doi.org\/10.1089\/10430349950016708","journal-title":"Hum Gene Ther"},{"issue":"6","key":"9_CR76","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/BF02369439","volume":"22","author":"L Chen","year":"1996","unstructured":"Chen L, Anton M, Graham FL (1996) Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 22(6):477\u2013488","journal-title":"Somat Cell Mol Genet"},{"issue":"11","key":"9_CR77","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/JVI.70.11.7498-7509.1996","volume":"70","author":"N Mittereder","year":"1996","unstructured":"Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70(11):7498\u20137509","journal-title":"J Virol"},{"issue":"1","key":"9_CR78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","volume":"36","author":"JV Maizel Jr","year":"1968","unstructured":"Maizel JV Jr, White DO, Scharff MD (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36(1):115\u2013125","journal-title":"Virology"},{"key":"9_CR79","series-title":"Ad proteins, RNA lifecycle, host interactions, and phylogenetics","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-1-59745-277-9_17","volume-title":"Adenovirus methods and protocols","author":"JJ Rux","year":"2007","unstructured":"Rux JJ, Burnett RM (2007) Large-scale purification and crystallization of adenovirus hexon. In: Wold WSM, Tollefson AE (eds) Adenovirus methods and protocols, Ad proteins, RNA lifecycle, host interactions, and phylogenetics, vol 2. Humana Press, Totowa, NJ, pp 231\u2013250. https:\/\/doi.org\/10.1007\/978-1-59745-277-9_17"}],"container-title":["Methods in Molecular Biology","Viral Vectors for Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9065-8_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T09:39:45Z","timestamp":1694597985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9065-8_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9781493990641","9781493990658"],"references-count":79,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9065-8_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"1 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}